Trial reportThe Journal of clinical psychiatry2020
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Trial report in The Journal of clinical psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02818751 (Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms.Journal of child and adolescent psychopharmacology · 2025Pooled it
- The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults.Journal of child and adolescent psychopharmacology · 2024Pooled it
- Efficacy and Safety of Escitalopram in Alleviating Depression and Anxiety Symptoms in COPD Patients: A Randomized Double-Blind Placebo-Controlled Trial.International journal of chronic obstructive pulmonary disease · 2026Trial
- Circulating endocannabinoids in children and adolescents: associations with anxiety and the impact of selective serotonin reuptake inhibitors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Executive Functioning in Pediatric Anxiety and Its Relationship to Selective Serotonin Reuptake Inhibitor Treatment Response: A Double-Blind, Placebo-Controlled Trial.Journal of child and adolescent psychopharmacology · 2022Trial
- Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.Journal of the American Academy of Child and Adolescent Psychiatry · 2021Trial
- Exploring the impacts of flavonoid compounds on escitalopram metabolism: a combined in vitro and in vivo study.Molecular diversity · 2026Article
- Effectiveness of selective serotonin reuptake inhibitors in inpatients with selective mutism compared to social anxiety disorder: an observational study.European child & adolescent psychiatry · 2026Observational
- Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms.Frontiers in pharmacology · 2026Article
- Distinct Trajectories of Amygdala Connectivity Patterns Characterize Remission vs. Non-Remission in Patients With Major Depressive Disorder.Depression and anxiety · 2026Article
- Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy.Biomedicines · 2025Review
- Electronically Monitored Antidepressant Adherence in Adolescents with Anxiety Disorders: A Pilot Study.Journal of child and adolescent psychopharmacology · 2025Article
- The microbiota-gut-brain axis in depression: unraveling the relationships and therapeutic opportunities.Frontiers in immunology · 2025Review
- Machine Learning-Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents.Clinical pharmacology and therapeutics · 2024Article
- Influence ofCanadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Article
- A Study of the Relationship between Inflammatory Immune Function and Intestinal Flora in Adolescent Patients with First-Episode Depression.Actas espanolas de psiquiatria · 2024Article
- Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.Journal of child and adolescent psychopharmacology · 2024Article
- Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.Clinical pharmacokinetics · 2023Article
- State of the Evidence for Use of Psychotropic Medications in School-Age Youth.Children (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundSelective serotonin reuptake inhibitors (SSRIs) are commonly used to treat pediatric anxiety disorders, including generalized anxiety disorder (GAD); however, their efficacy and tolerability are difficult to predict. This study evaluated the efficacy and tolerability of escitalopram in adolescents with GAD (DSM-IV-TR) and the impact of variants in HTR2A and serotonin transporter (SLC6A4) genes and cytochrome P450 2C19 (CYP2C19) phenotypes on response as well as CYP2C19 phenotype on escitalopram pharmacokinetics from February 2015 through November 2018.
methodsPatients were treated with escitalopram (forced titration to 15 mg/d, then flexible titration to 20 mg/d) (n = 26, mean ± SD age: 14.8 ± 1.7 years) or placebo (n = 25, mean ± SD age: 14.9 ± 1.6 years) for 8 weeks. Outcomes were the change in scores on the Pediatric Anxiety Rating Scale (PARS) and Clinical Global Impressions (CGI) scales as well as vital signs and adverse events. Plasma escitalopram and desmethylcitalopram area under the curve during 24 hours (AUC0-24) and maximum concentration (Cmax) were determined and compared across CYP2C19 phenotypes.
resultsEscitalopram was superior to placebo for mean ± SD baseline-to-endpoint change in PARS (-8.65 ± 1.3 vs -3.52 ± 1.1, P = .005) and CGI scores, and increasing CYP2C19 metabolism was associated with decreases in escitalopram Cmax (P = .07) and AUC0-24 (P < .05). Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo.
conclusionsEscitalopram reduces anxiety symptoms, and pharmacogenetics variables influence the trajectory and magnitude of improvement. Variation in CYP2C19 metabolism accounts for significant differences in escitalopram pharmacokinetics, raising the possibility that CYP2C19 phenotype should be considered when prescribing escitalopram.
trial registrationClinicalTrials.gov identifier: NCT02818751.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.